Carcinome séreux de bas grade ovarien à un stade avancé : étude rétrospective sur 34 patientes en résection complète

Zaccarini, François; Roosen, Alice; Sanson, Claire; Maulard, Amandine; Schérier, S.; Pautier, Patricia; Leary, Alexandra; Chargari, Cyrus; Morice, Philippe; Gouy, Sébastien

doi:10.1016/j.gofs.2021.04.009

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective analysis at Gustave Roussy Institut including 34 patients with LGSC stage IIIb-IV, NACT was administered in 16 patients (47.1%), and complete response (CR) never occurred, which emphasizes the chemoresistance of this disease and the importance of maximum surgical effort ( 53 ).…”

Section: Systemic Chemotherapymentioning

confidence: 99%

Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review

Giannecchini,

da Silva,

de Oliveira Bretas

et al. 2024

Front. Med.

View full text Add to dashboard Cite

By presenting a comprehensive analysis of low-grade serous carcinomas (LGSCs), a subset of epithelial ovarian cancers, this review delves into their distinct molecular characteristics, clinicopathological features and systemic therapy options, emphasizing their differences from high-grade serous carcinomas (HGSCs). Notably, LGSCs exhibit prevalent RAS/RAF/MEK/MAPK pathway activation, KRAS and BRAF mutations, and infrequent p53 mutations. While chemotherapy is commonly employed, LGSCs display lower responsiveness compared to HGSCs. Hormone therapy, particularly endocrine maintenance therapy, is explored due to the higher estrogen receptor expression. Novel therapeutic approaches involving CDK4/6 inhibitors, MEK inhibitors, and antiangiogenic agents like bevacizumab are also investigated. Ongoing clinical trials are striving to enhance LGSC treatment strategies, offering valuable insights for future therapeutic advancements in this challenging ovarian cancer subtype.

show abstract

Section: Systemic Chemotherapymentioning

confidence: 99%